Eli Lilly reaches $2.75 billion deal with Insilico to commercialize AI-developed drugs

Eli Lilly agreed to a deal that could total $2.75 billion to bring Hong Kong-based Insilico Medicine’s AI-designed drug candidates to the global market, including $115 million up front and remaining payments tied to regulatory and commercial milestones and royalties.

Eli Lilly has reached an agreement with Insilico Medicine to bring drugs developed using artificial intelligence to the global market. The companies announced the deal on Monday and said Insilico will receive $115 million up front, with the total package reaching up to $2.75 billion depending on regulatory and commercial milestones, plus royalties. Insilico has reported using generative AI to develop at least 28 drug candidates, with nearly half at clinical stages. The two firms have cooperated before under an AI software licensing agreement signed in 2023. Key details: - The agreement includes a $115 million upfront payment and up to $2.75 billion in milestone and royalty payments, as announced by the companies. - Insilico has developed at least 28 drug candidates using generative AI, and the company reported that nearly half are at clinical stages. - As part of the deal, Insilico will join Eli Lilly's Gateway Labs community for biotech development. - The companies previously signed an AI-based software licensing agreement in 2023. - The article mentions Insilico went public in Hong Kong in December and that its shares are up more than 50% year-to-date. - Eli Lilly CEO David A. Ricks attended a forum in Beijing recently; Lilly has announced plans to invest $3 billion in China over the next decade and reported that slightly less than 3% of its revenue came from China last year. Summary: The agreement expands Lilly's access to AI-discovered therapeutic candidates while providing Insilico with development and commercialization support. A substantial portion of the deal value is contingent on future regulatory and commercial outcomes, so long-term results will depend on those processes. Undetermined at this time.